ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysis
- Authors:
- A Clamp, I Mcneish, D Radice, R Lord, A Michael, A Cook, R Agarwal, A Walther, S Blagden, D O'Donnell, JD Brenton, S Sundar, C Sessa, L Murphy, F Schiavone, A Gentry-Maharaj, R Kaplan, MK Parmar, JA Ledermann
- Journal:
- International Journal of Gynecological Cancer
- Citation info:
- 36(2):102893
- Publication date:
- 1st Feb 2026
- Full text
- DOI